Document is current
Any future updates will be listed below
-
Authors
Foucrier, Arnaud
Dessalle, Thomas
Tuffet, Sophie
Federici, Laura
Dahyot‑Fizelier, Claire
Barbier, François
Pottecher, Julien
Monsel, Antoine
Hissem, Tarik
Lefrant, Jean‑Yves
Demoule, Alexandre
Constantin, Jean‑Michel
Rousseau, Alexandra
Simon, Tabassome
Leone, Marc
Bouglé, Adrien
,
Bouglé, Adrien
Amour, Julien
Dessalle, Thomas
Zegdi, Florence Bellenfant
Cholley, Bernard
Massot, Julien
Constantin, Jean-Michel
Demoule, Alexandre
Mayaux, Julien
Dubée, Vincent
Dupont, Hervé
Duranteau, Jacques
Federici, Laura
Foucrier, Arnaud
Geeraerts, Thomas
Guichon, Céline
Kalfon, Pierre
Kipnis, Éric
Lasocki, Sigismond
Lefrant, Jean-Yves
Legrand, Matthieu
Leone, Marc
Lescot, Thomas
Lévy, Bruno
Cousson, Joël
Montravers, Philippe
Tanaka, Sébastien
Novy, Emmanuel
Ouattara, Alexandre
Payen, Jean-François
Picard, Walter
Poète, Pascale
Pottecher, Julien
Quesnel, Christophe
Fartoukh, Muriel
Tesniere, Anoine
Fromentin, Mélanie
Rouby, Jean-Jacques
Lu, Qin
Langeron, Olivier
Squara, Pierre
Levesque, Eric
Mongardon, Nicola
,
Simon, Tabassome
Berard, Laurence
Cachanado, Marine
Soussi, Nora
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02634411 at ClinicalTrials.govDocuments that mention this clinical trial
Association between combination antibiotic therapy as opposed as monotherapy and outcomes of ICU patients with Pseudomonas aeruginosa ventilator-associated pneumonia: an ancillary study of the iDIAPASON trial
https://doi.org/10.1186/s13054-023-04457-y
- License Information
-
More Information
Article History
Received: 11 February 2023
Accepted: 20 April 2023
First Online: 30 May 2023
Declarations
:
: iDiapason trial has been conducted in accordance with the Declaration of Helsinki and French laws and regulations. The study has received its approval from the French ethics committee (Comité de Protection des Personnes Ile de France VI) as well from the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé) (EudraCT 2015-003102-17). The iDIAPASON study has received its approval from the French ethical committee (Comité de Protection des Personnes Ile de France VI) as well from the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé). Written informed consent was sought before inclusion or from a patient’s relative or an emergency inclusion if their absence according to French law.
: Not applicable.
: The authors declare that they have no competing interests.
